Akèy › Kansè tete negatif triple › Kalifòni › San Diego
Etid klinik pou Kansè tete negatif triple nan San Diego, CA
13 etid pou Kansè tete negatif triple ap chèche patisipan nan sit nan ak bò kote San Diego (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Ap rekriteFaz 3
- Scripps Cancer Center ( Site 0052), La Jolla · 11 mi lwen
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- University of San Diego Moores Cancer Center, La Jolla · 11 mi lwen
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Ap rekriteFaz 1
- University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla · 11 mi lwen
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Ap rekriteEtid obsèvasyon
- University of California San Diego, La Jolla · 11 mi lwen
Intratumoral N17350 in Advanced Solid Tumors
Ap rekriteFaz 1/2
- Scripps Clinic Torrey Pines - La Jolla, San Diego
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Ap rekriteFaz 1
- University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla · 11 mi lwen
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1
- UC San Diego Moores Cancer Center, La Jolla · 11 mi lwen
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Ap rekriteFaz 1/2
- University of California, San Diego; Moores Cancer Center, San Diego
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Ap rekriteFaz 2
- University of California San Diego, La Jolla · 11 mi lwen
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
Ap rekriteFaz 1
- UCSD Moores Cancer Center, La Jolla · 11 mi lwen
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Ap rekriteFaz 1/2
- UCSD Moores Cancer Center, La Jolla · 11 mi lwen
A Beta-only IL-2 ImmunoTherapY Study
Ap rekriteFaz 1/2
- Sharp Memorial Hospital, San Diego
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Ap rekriteFaz 1
- UC San Diego Moores Cancer Center, La Jolla · 11 mi lwen
Etid Kansè tete negatif triple nan lòt vil
- Houston, TX42 etid
- New York City, NY31 etid
- Nashville, TN27 etid
- Los Angeles, CA26 etid
- Boston, MA26 etid
- San Antonio, TX22 etid
- St. Louis, MO21 etid
- Arlington, VA20 etid
- Atlanta, GA20 etid
- Dallas, TX18 etid
- Columbus, OH16 etid
- Chicago, IL16 etid
Lòt etid nan San Diego
- Kansè Poumon ki pa ti selil48 etid
- Kansè nan tete42 etid
- Kansè (tout kalite)32 etid
- Kansè pwostat31 etid
- Kansè Metastatik30 etid
- Kansè kolorektal25 etid
- Kansè ovè24 etid
- Kansè pankreyas24 etid
- Ensifizyans kadyak23 etid
- Obèsite23 etid
- Kansè poumon23 etid
- Depresyon21 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 7, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.